TEVA stock icon

Teva Pharmaceuticals
TEVA

$16.38
2.1%

Market Cap: 18.6B

 

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 37,851

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 12 analysts
0
News positive %
of 10 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

58% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 45

46% more call options, than puts

Call options by funds: $371M | Put options by funds: $255M

33% more repeat investments, than reductions

Existing positions increased: 170 | Existing positions reduced: 128

32% more capital invested

Capital invested by funds: $6.09B [Q4 2023] → $8.05B (+$1.97B) [Q1 2024]

25% more funds holding in top 10

Funds holding in top 10: 20 [Q4 2023] → 25 (+5) [Q1 2024]

6% more funds holding

Funds holding: 435 [Q4 2023] → 461 (+26) [Q1 2024]

0.69% less ownership

Funds ownership: 51.62% [Q4 2023] → 50.94% (-0.69%) [Q1 2024]

Research analyst outlook

12 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$11
33%
downside
Avg. target
$18.25
11%
upside
High target
$24
47%
upside

12 analyst ratings

10 positive
83%
neutral
17%
negative
0%
UBS
Ashwani Verma
47%upside
$24
Buy
Maintained
10 Jul 2024
Jefferies
Glen Santangelo
40%upside
$23
Buy
Maintained
27 Jun 2024
Barclays
Balaji Prasad
28%upside
$21
Overweight
Maintained
5 Jun 2024
B of A Securities
Jason Gerberry
28%upside
$21
Buy
Maintained
30 May 2024
Piper Sandler
David Amsellem
22%upside
$20
Overweight
Reiterated
13 May 2024

Financial journalist opinion

Based on 10 articles about TEVA published over the past 30 days